Navigation Links
Breast cancer patients place huge emphasis on gene expression profiling test
Date:4/28/2014

TORONTO, April 28, 2014Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research suggests.

Current guidelines for treating early-stage breast cancercancer that has not spread to nearby lymph nodes or other parts of the bodyresult in thousands of women receiving chemotherapy without benefitting from it.

A gene expression profiling test can help differentiate women who might benefit from chemotherapy versus those that might not. The test analyzes the patterns of 21 different genes within the cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.

Dr. Yvonne Bombard, a genomics and health services researcher in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, said women she interviewed understood the test would indicate whether chemotherapy would be beneficial to them.

But, she said, many thought the test reflected their unique circumstances and did not understand that their test result was based on larger population statistics.

Her findings have been published online in the journal Current Oncology.

"Patients often viewed their GEP results as providing information that was more scientifically valid, uniquely personalized and emotionally significant than any other information they had received," Dr. Bombard said. "For many, the test was a transformational element that empowered them, allowed them to feel confident in their decisions and may even have rescued them from unnecessary chemotherapy."

The GEP test was a main determinant of patients' chemotherapy decisions, despite their misunderstanding of the test and its validity.

"GEP is one of many factors that women in consultation with their oncologists, should consider when choosing treatment for early stage breast cancer," said Dr. Maureen Trudeau, a medical oncologist of the Breast Care team and head of the Medical Oncology Program at Sunnybrook's Odette Cancer Centre, and study co-author. "The GEP test does not replace standard prognostic information but adds one more piece of information."

Clinical guidelines suggest the majority of the 22,600 Canadians whose breast cancer tests negative for human epidermal growth factor receptor 2 (HER2) should be offered chemotherapy. Yet only 15 per cent of such cancers will recur, suggesting that about 8,500 Canadian patients are treated without benefit each year.


'/>"/>

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital
Source:Eurekalert  

Related biology news :

1. Protein jailbreak helps breast cancer cells live
2. Breast cancer risk gene discovery fast tracked by new technology
3. A new breast cancer susceptibility gene
4. Mechanism found connecting metastatic breast cancer and arthritis
5. Detecting breast cancers fingerprint in a droplet of blood
6. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
7. High levels of TRAIL protein in breast milk might contribute to anticancer activity
8. Fourth IMPAKT Breast Cancer Conference
9. Breast cancer in young women: A distinct disease
10. Immune-response genes affecting breast tumor eradication
11. New data improve understanding of breast cancers multiple varieties
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast cancer patients place huge emphasis on gene expression profiling test
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... April 20, 2017 , ... Husson University will ... community’s growing body of knowledge during its Eighth Annual Research and Scholarship ... adjacent Darling Atrium. During the event, undergraduates, graduate students, and faculty members from ...
(Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... Parallel6™ ... clinical trials worldwide, announced today that they were named one of the 2017 ... covers the latest developments in the pharmaceutical industry. , “We take pride in honoring ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today ... move comes after the company changed focus to making analytical tools for biopharmaceutical ... our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and ...
Breaking Biology Technology: